Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
26.89
+1.49 (5.87%)
At close: Dec 5, 2025, 4:00 PM EST
26.88
-0.01 (-0.04%)
After-hours: Dec 5, 2025, 7:59 PM EST
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $11.13M in the twelve months ending September 30, 2025, down -52.08% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$11.13M
Revenue Growth
-52.08%
P/S Ratio
109.71
Revenue / Employee
$69,566
Employees
160
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CAPR News
- 11 hours ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 1 day ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 days ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga
- 3 days ago - Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial - Benzinga
- 3 days ago - Capricor's muscle disorder cell therapy succeeds in late-stage study - Reuters
- 11 days ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga
- 25 days ago - Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel - GlobeNewsWire